Safinamide prevents lipopolysaccharide (LPS)-induced inflammation in macrophages by suppressing TLR4/NF-κB signaling
LuLu Qian1, Jun-Zhao Li1, XueMei Sun1
1Department of Pediatrics, Taizhou People's Hospital, Taizhou, Jiangsu 225300, China.
Abstract:
Inflammation is a basal host defense response that eliminates the causes and consequences of infection and tissue injury. Macrophages are the primary immune cells involved in the inflammatory response. When activated by LPS, macrophages release various pro-inflammatory cytokines, chemokines, inflammatory mediators, and MMPs. However, unbridled inflammation causes further damage to tissues. Safinamide is a selective and reversible monoamine oxidase B (MAOB) inhibitor that has been used for the treatment of Parkinson's disease. In this study, we aimed to investigate whether safinamide has effects on LPS-treated macrophages. Our results show that safinamide inhibited the expression of pro-inflammatory cytokines such as IL-1α, TNF-α, and IL-6. Furthermore, safinamide suppressed the production of CXCL1 and CCL2, thereby preventing leukocyte migration. In addition, safinamide reduced iNOS-derived NO, COX-2-derived PGE2, MMP-2, and MMP-9. Importantly, the functions of safinamide mentioned above were found to be dependent on its inhibitory effect on the TLR4/NF-κB signaling pathway. Our data indicates that safinamide may exert a protective effect against inflammatory response.
Insights
Safinamide, a Parkinson's disease drug, was found to reduce inflammatory responses in macrophages. It inhibited key inflammatory molecules and pathways, suggesting a potential protective role against inflammation.
Area of Science:
- Immunology
- Pharmacology
- Cell Biology
Background:
- Inflammation is a critical defense mechanism involving macrophages.
- Uncontrolled inflammation can lead to tissue damage.
- Safinamide is a known monoamine oxidase B (MAOB) inhibitor used for Parkinson's disease.
Purpose of the Study:
- To investigate the anti-inflammatory effects of safinamide on lipopolysaccharide (LPS)-activated macrophages.
- To explore the molecular mechanisms underlying safinamide's action.
Main Methods:
- Macrophages were treated with LPS and safinamide.
- Expression of pro-inflammatory cytokines (IL-1α, TNF-α, IL-6) was measured.
- Production of chemokines (CXCL1, CCL2), nitric oxide (NO), prostaglandin E2 (PGE2), and matrix metalloproteinases (MMPs) was assessed.
- The role of the TLR4/NF-κB signaling pathway was investigated.
Main Results:
- Safinamide significantly inhibited the expression of IL-1α, TNF-α, and IL-6.
- Safinamide suppressed CXCL1 and CCL2 production, reducing leukocyte migration.
- Safinamide decreased iNOS-derived NO, COX-2-derived PGE2, MMP-2, and MMP-9.
- These effects were dependent on the inhibition of the TLR4/NF-κB pathway.
Conclusions:
- Safinamide demonstrates potent anti-inflammatory properties in macrophages.
- Safinamide modulates key inflammatory mediators and pathways.
- Safinamide may offer a protective effect against inflammatory conditions.
More Related Videos
09:31Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
12:47Using RNA-interference to Investigate the Innate Immune Response in Mouse Macrophages
Published on: November 3, 2014
Related Concept Videos
Inflammation
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Formation of Lipopolysaccharides
